Second malignancies in multiple myeloma; emerging patterns and future directions Review

   


Authors: Maclachlan, K.; Diamond, B.; Maura, F.; Hillengass, J.; Turesson, I.; Landgren, C. O.; Kazandjian, D.
Review Title: Second malignancies in multiple myeloma; emerging patterns and future directions
Abstract: The changing landscape of treatment options for multiple myeloma has led to a higher proportion of patients achieving deep, long-lasting responses to therapy. With the associated improvement in overall survival, the development of subsequent second malignancies has become of increased significance. The risk of second malignancy after multiple myeloma is affected by a combination of patient-, disease- and therapy-related risk factors. This review discusses recent data refining our knowledge of these contributing factors, including current treatment modalities which increase risk (i.e. high-dose melphalan with autologous stem cell transplant and lenalidomide maintenance therapy). We highlight emerging data towards individualized risk- and response-adapted treatment strategies and discuss key areas requiring future research. © 2020 Elsevier Ltd
Keywords: treatment response; genetics; lenalidomide; clinical feature; review; cancer patient; drug megadose; cancer incidence; neoplasms; cancer susceptibility; bortezomib; multiple myeloma; risk factors; melphalan; autologous stem cell transplantation; transplantation; age; comorbidity; behavior; second cancer; autoimmune disease; environmental factor; ethnicity; sex; carfilzomib; personalized medicine; second primary; clinical outcome; autologous; human; priority journal; elotuzumab; daratumumab; immunological antineoplastic agent
Journal Title: Best Practice and Research: Clinical Haematology
Volume: 33
Issue: 1
ISSN: 1521-6926
Publisher: Elsevier Inc.  
Date Published: 2020-03-01
Start Page: 101144
Language: English
DOI: 10.1016/j.beha.2020.101144
PUBMED: 32139010
PROVIDER: scopus
PMCID: PMC7544243
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078481537&doi=10.1016%2fj.beha.2020.101144&partnerID=40&md5=19da61cec09fa9da6dd2ca64d2a09b0f
Notes: Review -- Export Date: 1 April 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Carl Ola Landgren
    336 Landgren
  2. Francesco Maura
    56 Maura
  3. Benjamin Diamond
    33 Diamond
  4. Kylee Maclachlan
    143 Maclachlan
Related MSK Work